Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor <scp>ECOG</scp> Performance Status With Relapsed or Refractory Large B‐Cell Lymphoma After 2 or More Lines of Prior Therapy”

Authors: Abstract: No abstract found.

Published: 2024-12-12

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27551

Keywords: No keywords found.

Abstract:
No abstract found.

Source: